Biodesix, Inc. (BDSX)
NASDAQ: BDSX · Real-Time Price · USD
0.3835
-0.0275 (-6.69%)
At close: Aug 13, 2025, 4:00 PM
0.3836
+0.0001 (0.03%)
Pre-market: Aug 14, 2025, 4:33 AM EDT
Biodesix Revenue
Biodesix had revenue of $20.02M in the quarter ending June 30, 2025, with 11.68% growth. This brings the company's revenue in the last twelve months to $76.56M, up 25.70% year-over-year. In the year 2024, Biodesix had annual revenue of $71.32M with 45.30% growth.
Revenue (ttm)
$76.56M
Revenue Growth
+25.70%
P/S Ratio
0.74
Revenue / Employee
$280,425
Employees
273
Market Cap
56.23M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 71.32M | 22.24M | 45.30% |
Dec 31, 2023 | 49.09M | 10.88M | 28.46% |
Dec 31, 2022 | 38.21M | -16.29M | -29.89% |
Dec 31, 2021 | 54.51M | 8.95M | 19.64% |
Dec 31, 2020 | 45.56M | 21.01M | 85.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BDSX News
- 4 days ago - Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Biodesix Announces Second Quarter 2025 Results and Highlights - GlobeNewsWire
- 8 days ago - Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 20 days ago - Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 2 months ago - Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs - GlobeNewsWire
- 2 months ago - Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Biodesix to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS - GlobeNewsWire